ReviewKidney international reports2023
COVID-19 and Glomerular Diseases.
Review in Kidney international reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- Post-nephrectomy outcomes in COVID-19 and non-COVID-19 Patients using ACEi, ARB and SGLT2i: a N3C database study.International urology and nephrology · 2026Article
- Clinical characteristics and mortality outcomes of acute kidney injury following COVID-19 infection in patients with chronic kidney disease at different stages.BMC infectious diseases · 2025Article
- Long COVID and the kidney.Nature reviews. Nephrology · 2025Review
- Collapsing Glomerulopathy in Brazil: A Nationwide Descriptive Study.Nephrology (Carlton, Vic.) · 2025Article
- Long-term renal consequences of COVID-19. Emerging evidence and unanswered questions.International urology and nephrology · 2025Review
- COVID-19 associated acute kidney injury.Infectious diseases & immunity · 2025Review
- Multiple occurrences of membranous nephropathy complicated with anti-glomerular basement membrane antibody and anti-neutrophil cytoplasm antibody double-negative crescentic formation since the COVID-19 pandemic: A case series.The Journal of international medical research · 2025Article
- Crescentic Glomerulonephritis Possibly Caused by COVID-19 Infection.Journal of clinical medicine · 2025Article
- Anti-glomerular basement membrane disease superimposed on membranous nephropathy after coronavirus disease 2019: A case report.The Journal of international medical research · 2025Article
- A case of de novo glomerulonephritis following COVID-19 in a patient with preexistent IgA vasculitis.CEN case reports · 2025Article
- A scoping review on adult patients with de novo glomerular diseases following COVID-19 infection or vaccine.International urology and nephrology · 2025Article
- SARS-CoV-2 Protein Deposition Enhances Renal Complement Activation and Aggravates Kidney Injury in Membranous Nephropathy After COVID-19.Kidney international reports · 2024Article
- Concurrent glomerular PCDH7 deposits in PLA2R-associated membranous nephropathy.CEN case reports · 2024Article
- An Update on Viral Infection-Associated Collapsing Glomerulopathy.Advances in kidney disease and health · 2024Review
- The impact of mild and moderate COVID-19 infection on the progression of kidney dysfunction in patients with IgA nephropathy.Clinical kidney journal · 2024Article
- JAK inhibition during the early phase of SARS-CoV-2 infection worsens kidney injury by suppressing endogenous antiviral activity in mice.American journal of physiology. Renal physiology · 2024Article
- Incidence of Common Glomerular Diseases Other Than Collapsing Glomerulopathy is Not Increased After SARS-CoV-2 Infection.Kidney international reports · 2024Article
- Glomerulonephritis following COVID-19 infection or vaccination: a multicenter study in South Korea.Kidney research and clinical practice · 2024Article
- Tip Lesion Most Frequent FSGS Variant Related to COVID-19 Vaccine: Two Case Reports and Literature Review.Vaccines · 2024Article
- The Time-Varying Impact of COVID-19 on the Acute Kidney Disorders: A Historical Matched Cohort Study and Mendelian Randomization Analysis.Health data science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is a systemic disease, and the kidney is one of the target organs of infection. Kidney injury is common and can occur in up to 40% of patients. Several glomerular diseases have been reported in association with COVID-19. Some are likely related to COVID-19 whereas many are likely coincidental. Glomerular diseases that are frequently reported in COVID-19 and have a plausible mechanistic explanation are likely to be related to COVID-19. In contrast, glomerular diseases that are seldom reported and have no known plausible mechanism, are likely to be unrelated. Collapsing glomerulopathy (CG) is by far the most prevalent. Its association with COVID-19, resembling HIV and CG, led to the newly proposed term "COVID-19 associated nephropathy" or "COVAN." High-risk APOL1 genotypes are the major risk factor in COVAN patients. Podocytopathy, membranous nephropathy (MN), pauci-immune crescentic glomerulonephritis (GN), and thrombotic microangiopathy (TMA) are also reported. In kidney allografts, CG remains the most common glomerular pathology. Patients typically present with acute kidney injury (AKI) or abnormal urinary findings at the time of or shortly after COVID-19 diagnosis. Treatment of glomerular disease in patients with COVID-19 is challenging. Providers should cautiously consider balancing risks and benefit of immunosuppression, particularly in patients with active diseases. Short-term outcomes vary but generally remain poor with high morbidity and mortality. Future study of long-term outcomes is needed to improve our understanding of glomerular disease associated with COVID-19.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.